This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
AstraZeneca (AZN.L) – Lynparza approved in European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer. Closing Price 4449.00p (Reuters)
Galliford Try (GFRD.L) – Wins estates contract with UK ministry of defence. Appointed to mod's next generation estates contract (NGEC) framework for capital works projects in Scotland. Four year framework is worth up to £250m for projects with individual values of up to £12m. Closing price 1214.00p (Reuters)
Shire (SHP.L) – Whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc. Closing Price 4522.00p (Reuters)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| Babcock International Group | BAB.L | -1.23% | -0.51% | -2.45% |
| BP | BP.L | 3.54% | 3.58% | -1.61% |
| Royal Dutch Shell | RDSB.L | 4.99% | 5.67% | -0.08% |
| Tullow Oil | TLW.L | 3.59% | 4.35% | -2.07% |
| BG Group | BG.L | 3.32% | 4.21% | -3.37% |
| Petrofac | PFC.L | 1.74% | 2.54% | -4.48% |
| BT | BT.A.L | -0.89% | -0.07% | -1.71% |
| Dixons Carphone | DC.L | 3.05% | 4.57% | 1.49% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research